Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal viewFrederick W. Thielen, Annemieke van Dongen‐Leunis, Alexander M. M. Arons et al.|European Journal Of Haematology|2020Cited by 42